




Rivastigmine Transdermal Patch

Lisidiming Toupitieji

S -N- -N- -3-[1-()]-



$C_{14}H_{22}N_2O_2$

250.34

[(2-) ,]

/ /

4.6mg/24

1 4.6mg/24

2 9.5mg/24

- 50kg

-

		4.6mg/24	9.5mg/24	13.3mg/24
17.4mg/24			13.3mg/24	17.4mg/24
				1
	9.5mg/24			
/				/
		17.4mg/24	*	
		9.5mg/24		
2				

		1	2			
(≥10%)		(1%~10%	1%)	(0.1%~1%	0.1%)	(0.01%~0.1%
0.01%)		(<0.01%)				
1	B	U				

*		13.3mg/24		
*		17.4mg/24		
**	24		“	”
***	24			“ ”

/

	18 6.2	57 18.8	50 17.0	10 3.3	75 12.6
	18 6.2	31 10.2	16 5.4	10 3.3	49 8.2
	8 2.7	23 7.6	16 5.4	4 1.3	31 5.2
	7 2.4	21 6.9	22 7.5	7 2.3	28 4.7
	2 0.7	15 5.0	12 4.1	3 1.0	17 2.9
	10 3.4	13 4.3	18 6.1		

2.2%

3.7%

-

- /
-

3

4.6mg/24

/

/

QT /

•

/

/

/

/

/

/

88% 65

55% 75

/

P450

/

/

/

/

/

β-_____

β-

/

β-

β-

n=75

549

12mg/

/

/

23%

/

/

/

/

/

24 48

24

10-20

24

ADAS-Cog -
ADCS-CGIC -
ADCS-ADL -

3 24

4


4	3	24		
ITT-LOCF		9.5mg/24 N=251	12mg/ N=256	N=282
ADAS-Cog		n=248	n=253	n=281
±		27.0±10.3	27.9±9.4	28.6±9.9
24	±	-0.6±6.4	-0.6±6.2	1.0±6.8
	p	0.005* ¹	0.003* ¹	
ADCS-CGIC		n=248	n=253	n=278
±		3.9±1.20	3.9±1.25	4.2±1.26
	p	0.010* ²	0.009* ²	
ADCS-ADL		n=247	n=254	n=281
±		50.1±16.3	49.3±15.8	49.2±16.0
24	±	-0.1±9.1	-0.5±9.5	-2.3±9.4
	p	0.013* ¹	0.039* ¹	

* p≤0.05
ITT 1 LOCF
ADAS-Cog
ADCS-ADL
2 CMH van Elteren ADCS-CGIC <4

24 5
ADAS-Cog 4 ADCS-CGIC ADCS-ADL

	%		
	9.5mg/24	12mg/ [®]	
ITT-LOCF	N=242	N=248	N=276
ADAS-Cog 4 ADCS-CGI ADCS-ADL	17.4	19.0	10.5
p	0.037*	0.004*	



* p<0.05



	(13.3mg/24h) N = 265	(9.5mg/24h) N = 271	(13.3mg/24h) (9.5mg/24h)
DLSM			
95% CI			
P			

	(13.3mg/24h) N = 265	(9.5mg/24h) N = 271	-	(13.3mg/24h) (9.5mg/24h)
--	-------------------------	------------------------	---	-----------------------------

-48



/ kg 43% C_{max} 49% AUC_{0-24h}
74% 103%

45% C_{max} 43% AUC_{0-24h}

71% 73%

		NAP-226-90	
	65kg	35kg	2
100kg			

15

15

264670

0535-6717618

0535-6717718

www.luye.cn

_____?

¶

¶

¶

1

¶

¶

¶

¶

¶

¶

24

¶

14

¶

¶

¶

2

¶

3

¶

¶

1

1

?

A

¶

¶

¶

¶

A





6

¶

¶

¶

¶
